This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More
DDW Editor Reece Armstrong speaks to Ron Alfa, CEO & Co-founder at NOETIK, about the company’s mission to utilise artificial intelligence (AI) and spatial biology to develop better immunotherapies for cancer patients. Reece A: What are some of the human limitations to current drug discovery research for immunotherapies?… Read More
A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The contract was awarded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD)… Read More
Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. Financial landscape In 2023, life science companies experienced… Read More
DDW Editor Reece Armstrong asks whether artificial intelligence (AI) is the magic bullet many think it is. To reflect on another year in pharma is to think of the major stories and trends that have made impact within the industry. Often this can be drug approvals, exciting research… Read More
DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the impact of artificial intelligence (AI), machine learning (ML) and automation in… Read More
As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. From finding potential active substances and identifying novel targets, to simulating how drugs will function in the human body and… Read More
As long as drug discovery, development and commercialisation activities and budgets continue to be managed in isolation, and Generative AI projects applied in a piecemeal fashion to individual applications, the pharma industry risks inhibiting the technology’s broader potential. Daniel Jamieson, CEO & founder of Biorelate, sets out his… Read More
Dr Mike Tarselli, Chief Scientific & Knowledge Officer at TetraScience, was Scientific Director of SLAS until 2020, and will be chairing his first event this year. He shares his insight with Megan Thomas. From pharma to non-profit “I probably wouldn’t have the role I have now… Read More
SandboxAQ has acquired Good Chemistry, a computational chemistry company that leverages AI, quantum and other advanced technologies to accelerate drug discovery. Good Chemistry, which spun out of 1Qbit in 2021, is SandboxAQ’s second acquisition and its first in the AI simulation sector. “Good Chemistry’s… Read More
Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. VRG50635 is a small molecule PIKfyve inhibitor and is reportedly one of the first drugs to enter clinical trials that was entirely… Read More
Massachusetts Institute of Technology (MIT) researchers have used deep learning to identify a new class of antibiotic candidates that can kill methicillin-resistant Staphylococcus aureus (MRSA). The study represents more good news in the battle against antimicrobial resistance, as researchers from Harvard University and Roche also recently announced… Read More
The SLAS Ignite Theater ‘Innovation & technology: from lab to patient’ will take place at SLAS2024 in Boston on 5 and 6 February 2024. The event will be curated by DDW and sponsored by Integra Biosciences and Hamamatsu Corporation, providing leading research from… Read More
Insilico Medicine has initiated the first-in-human study for ISM5411, a poly hydroxylase domain (PHD) 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD) designed by its generative AI platform. The company also plans to conduct global, multicentre Phase Ib trials in patients with ulcerative colitis… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where is the latest innovation in neuroscience?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Taking a new approach to tackle neurodegenerative diseases,… Read More
DDW’s Senior Digital Content Editor Diana Spencer reviews the year’s top ten articles. DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy… Read More
